Загрузка...
CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab
BACKGROUND: The mammalian target of rapamycin (mTOR) signaling pathway plays a pivotal role in numerous cellular processes involving growth, proliferation and survival. The purpose of this study was to investigate the anti-tumoral effect of the mTOR inhibitor (mTORi) CCI-779 in HNSCC cell lines and...
Сохранить в:
| Опубликовано в: : | J Transl Med |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4389307/ https://ncbi.nlm.nih.gov/pubmed/25890004 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-015-0456-6 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|